MTL

Accelerating medtech throughput

We partner with medtech to ship innovation faster, better, and cheaper — with more delight along the way. Independent, evidence-based evaluations build the trust between vendors and manufacturers it takes to get there.

The first evaluation cohort is forming now; evaluations proceed under federal SBIR funding upon award.

Why an independent lab

Throughput claims are easy to make and expensive to believe. Each engagement moves a candidate solution through four gates, from a scoped value hypothesis to benchmarked proof in your environment, so your team sees measured performance against your own constraints rather than a vendor’s demo.

How it works

Four gates to a defensible decision

Value Scope

Define the claim worth testing.

Benchmark

Independent measurement against reference workloads.

Proof of Value

Evidence from your environment and constraints.

Your decision

Adopt, pass, or wait — with documentation.

Led by

Shannon Lantzy

Founder & Chief Executive

Two decades at the intersection of regulatory science and medtech product development. Led modernization initiatives with FDA and advises executives at major device manufacturers on review and development throughput.

The next step

Adopt — or decline — on evidence, not promises

A 20–30 minute briefing covers how the evaluation works, what your team keeps regardless, and whether this cohort is a fit.